FDA Proposes Rule to Modernize Drug Manufacturing Registration
The proposal would cut duplicate filings for hub-and-spoke networks and improve FDA visibility into foreign supply chains, officials said.
- The FDA is proposing a rule allowing distributed manufacturing establishments to register as one single establishment, said Michael Davis, Acting Director of FDA's Center for Drug Evaluation and Research.
- Currently, regulations require each manufacturing unit in a network to register separately, creating unnecessary administrative burdens. The proposed rule would reduce registration costs and generate long-term efficiencies for both industry and the agency.
- Closing registration gaps for foreign establishments that manufacture drug components increases supply chain transparency. This allows the FDA greater ability to detect and respond to potential safety concerns in upstream supply chains.
- Under the proposed rule, units could be added, relocated, or removed through a streamlined update process. Companies would be required to notify the FDA in advance of any relocation, closing a gap in real-time oversight.
- This initiative builds on administration efforts to revitalize American pharmaceutical manufacturing and improve supply chain transparency. The proposal ensures Americans have reliable access to safe medicines while keeping regulatory frameworks aligned with innovation.
12 Articles
12 Articles
FDA Proposes Rule To Simplify Drug Manufacturing Registration
The U.S. Food and Drug Administration has proposed a rule to modernize registration requirements for drug manufacturers that operate through centralized production networks. According to the report, the proposal would allow companies using a "hub-and-spoke" manufacturing model to register multiple production sites as a single establishment rather than registering each facility separately.The report said the change is intended to simplify regulat…
FDA moves to expose hidden foreign drug factories, strengthen domestic production in sweeping rule proposal
The Food and Drug Administration is moving forward with a regulatory overhaul to limit U.S. reliance on foreign drugs and cut red tape to allow American manufacturers to fill the space, FOX Business has learned.The FDA is proposing a new rule Friday that aims to streamline processes for American drug manufacturers while toughening regulation for foreign ones.The FDA is launching a new website to go along with the overhaul that details all the wa…
Coverage Details
Bias Distribution
- 62% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
